Passage Bio, Inc. (PASG)

Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $22.35 million. The enterprise value is -$10.55 million.

Market Cap	22.35M
Enterprise Value	-10.55M

Important Dates

The next estimated earnings date is Wednesday, November 12, 2025, before market open.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 3.18 million shares outstanding. The number of shares has increased by 7.82% in one year.

Current Share Class	3.18M
Shares Outstanding	3.18M
Shares Change (YoY)	+7.82%
Shares Change (QoQ)	+2.04%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	41.97%
Float	2.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.58
P/TBV Ratio	0.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.65.

Current Ratio	3.05
Quick Ratio	2.91
Debt / Equity	0.65
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -88.27% and return on invested capital (ROIC) is -37.79%.

Return on Equity (ROE)	-88.27%
Return on Assets (ROA)	-33.20%
Return on Invested Capital (ROIC)	-37.79%
Return on Capital Employed (ROCE)	-91.47%
Revenue Per Employee	n/a
Profits Per Employee	-$947,583
Employee Count	60
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.88% in the last 52 weeks. The beta is 1.82, so Passage Bio's price volatility has been higher than the market average.

Beta (5Y)	1.82
52-Week Price Change	-51.88%
50-Day Moving Average	6.69
200-Day Moving Average	9.09
Relative Strength Index (RSI)	50.95
Average Volume (20 Days)	32,603

Short Selling Information

The latest short interest is 83,622, so 2.63% of the outstanding shares have been sold short.

Short Interest	83,622
Short Previous Month	97,134
Short % of Shares Out	2.63%
Short % of Float	2.92%
Short Ratio (days to cover)	2.59

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-54.33M
Pretax Income	-76.57M
Net Income	-56.86M
EBITDA	-52.49M
EBIT	-54.33M
Earnings Per Share (EPS)	-$18.34

Balance Sheet

The company has $57.63 million in cash and $24.73 million in debt, giving a net cash position of $32.90 million or $10.35 per share.

Cash & Cash Equivalents	57.63M
Total Debt	24.73M
Net Cash	32.90M
Net Cash Per Share	$10.35
Equity (Book Value)	38.26M
Book Value Per Share	12.04
Working Capital	40.51M

Cash Flow

In the last 12 months, operating cash flow was -$36.07 million and capital expenditures -$34,000, giving a free cash flow of -$36.10 million.

Operating Cash Flow	-36.07M
Capital Expenditures	-34,000
Free Cash Flow	-36.10M
FCF Per Share	-$11.36

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.82%
Shareholder Yield	-7.82%
Earnings Yield	-254.43%
FCF Yield	-161.56%

Analyst Forecast

The average price target for Passage Bio is $59.25, which is 742.82% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$59.25
Price Target Difference	742.82%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date	Jul 14, 2025
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	1